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A novel copper(II) heteroleptic complex of dipyrido[3,2-a:2′,3′-c]phenazine (dppz) and glycinato (gly) as chelat-
ing ancillary ligand, [Cu(dppz)(gly)]ClO4 (1), was synthesized and characterized. X-ray crystallography revealed
that the coordination geometry of the cationic [Cu(dppz)(gly)]+ unit is hexacoordinated and shows a distorted
octahedral coordination geometry in the solid state, with the N,N and N,O chelating atoms of dppz and glycinato,
respectively, in the square plane and in which the planar units are connected in a monodimensional polymeric
array by the apical copper coordination of the second carboxylic oxygen atom. Biological assays showed that 1
exhibits a remarkable anti-proliferative activity against the two human anaplastic thyroid cancer cell lines
8505c (BrafV600E/V600E) and SW1736 (BrafWT/V600E), in a dose- and time-dependent manner. In details,
the IC50 after 48 h of drug exposure was 2.86±0.54 μM for SW1736 and 1.05±0.48 μM for 8505c. On the
other hand, the IC50 shown by cis-diamminedichloroplatinum(II) (cisplatin) against the same cell lines was
2.50±0.40 μM and 6.03±0.78 μM, respectively. Optical microscopy observations, after 48 h of treatment,
showedmorphological cell changes typical of apoptosis, conﬁrmedbyDNA ladder assays. DNA interaction studies,
performed by UV absorption spectrophotometry, circular dichroism and viscosimetry, clearly showed that
[Cu(dppz)(gly)]ClO4 is a DNA-intercalator, with a DNA-binding constant, Kb, of 2.1×10
6 M−1, suggesting that
the mechanism of the cytotoxic activity can be related to its DNA-binding.
© 2012 Elsevier Inc. All rights reserved.
1. Introduction
There is nowadays increasingly growing interest toward the search
of new metal complexes showing anticancer properties, in particular
regarding ruthenium [1,2] and platinum [3] derivatives. Themainmoti-
vation of this research ﬁeld is to ﬁnd new active compounds toward
selected cancer cells with reduced side effects and able to overcome
the known “drug resistance” phenomenon occurringwith classical anti-
cancer drugs [4].
Anaplastic thyroid carcinoma (ATC) is a rare but aggressive thyroid
cancer. Besides radical surgery and radiotherapy, the combination of
chemotherapeutic drugs, such as doxorubicin and cisplatin, is at present
considered the best treatment strategy, although without noticeable
therapeutic success [5]. The chemotherapeutic effect of the classic anti-
cancer drugs, doxorubicin and cisplatin, is related to their tight binding
toDNA. In particular, cisplatin covalently binds to theN7 atomof guanine
[6,7] while doxorubicin is a DNA-intercalator [8].
Recently, copper(II) complexes have been considered as potential
anticancer compounds and, together with those of ruthenium(II), they
are considered among the most promising alternatives to cisplatin as
anticancer agents [9,10]. Interestingly, such anticancer activity has
been usually related to their DNA-binding properties.
Among the DNA-binders, particular interest has been devoted to
DNA-intercalators. In fact, it has been shown that the intercalation pro-
cess is often related to interesting biological effects [11]. It has been
reported that transition metal complexes with planar aromatic ligands
are oftenmore effective than the isolated ligands [12–14]. Several studies
have been conducted with heteroleptic complexes of the dipyrido
[3,2-a:2′,3′-c]phenazine (dppz) ligand, in particular with [M(phen)2-
dppz]2+/3+ complexes (M=Ru2+, Co3+, Cr3+, Fe2+, Ni2+, phen=
1,10-phenanthroline) [12,13,15–21] showing that the DNA intercalation
of dppz occurs from the major groove side [12,22]. Such compounds, in
particular [Ru(phen)2dppz]2+, have been recently used in cellular imag-
ing studies and for virus tracking [23]. Indeed, all knownmetal complexes
of dppz, independently of the nature of the ancillary ligands, are strong
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intercalating agents, with values of DNA-binding constants within 104–
107 M−1 [14,24–28]. Furthermore, it has been recently shown that a
cationic derivative of the dppz ligand shows analogous water solubility
and DNA-binding constant of the mentioned dppz metal complexes
[29,30]. Remarkably, many of these dppz complexes present promising
biological properties [31]. For example, the DNAbinding of [CuI(dppz)2]
BF4, [CuII(dppz)(NO3)]NO3 and [CuII(dppz)2(NO3)]NO3 has been relat-
ed to biological activity against Leishmania mexicana [26,32]. Recently,
the synthesis and DNA-binding of heteroleptic copper complexes of
dppz and amino acids have been reported [33–37]. Such compounds,
inter alia, have been proposed asmodels of bleomycins, naturally occur-
ring anti-tumor glycopeptide antibiotics. Deprotonated amino acids are
in fact efﬁcient chelating ligands providing stablemetal complexes [38].
We have recently studied the interaction of different copper(II)
complexes with native calf thymus DNA [39–43]. In a few cases, the
cytotoxic activity of these copper(II) complexes was correlated to
their DNA-binding properties [40,43].
As a continuation of this research line, in the present paper we report
on the synthesis and characterization,DNA-binding and anti-proliferative
activity against two ATC human cell lines of a copper(II) complex of dppz
and glycine. In fact, considering that both copper [44,45] and amino acids
are present within the intracellular environment, in our opinion they
could confer increased bio-compatibility to the resulting dppz containing
metal complex. Furthermore, it has been shown that the presence of
glycine in transition metal complexes confers on them interesting anti-
cancer properties [46–50].
2. Experimental
2.1. Materials and methods
Solvents and reagents (reagent grade) were all commercial and
used without further puriﬁcation. Lyophilized calf thymus DNA
(Fluka, BioChemika) was resuspended in 1.0 mM tris-hydroxymethyl-
aminomethane (Tris–HCl) pH=7.5 and dialyzed as described in the
literature [51]. DNA concentration, expressed in monomer units
([DNAphosphate]), was determined by UV spectrophotometry using
7000 M−1 cm−1 as a molar absorption coefﬁcient at 258 nm [52]. All
experiments were carried in Tris–HCl aqueous buffer at pH=7.5.
UV–visible (UV–vis) absorption spectra were recorded, at 25 °C, on
a Varian UV–vis Cary 1E double beam spectrophotometer, equipped
with a Peltier temperature controller, using 1 cm path-length cuvettes.
The titration was carried out adding increasing amounts of DNA stock
solution to a complex solution with constant concentration.
Circular dichroism spectra were recorded at 25 °C on a Jasco J-715
spectropolarimeter, using 1 cm path-length quartz cells. The titration
was carried out adding increasing amounts of complexes stock solutions
to a DNA solution with constant concentration.
Viscosity measurements were performed on a Ubbelodhe visco-
simeter, with a capillary diameter of 0.40 mm, maintained at 22.0±
0.1 °C, by a thermostatic bath. Flow time was measured with a digital
stopwatch; mean values of replicated measurements were used to
evaluate the viscosity of the samples. The cube root of the relative vis-
cosity, (η/η0)1/3, was plotted as a function of the [1]/[DNAphosphate]
molar ratio [53], where η0 is the viscosity of the DNA solution alone.
The kinematic viscosity was calculated by the following equation:
η=K (t−θ), where K=0.01 mm2/s and θ=0.04 s are two charac-
teristic constants of the Ubbelodhe micro-viscosimeter, and t (in s)
is the efﬂux time.
All the spectroscopic and viscosimetry measurements were recorded
after 24 h of the sample preparation.
2.2. Synthesis and characterization
The dppz ligand was synthesized and characterized as reported
[28,54]. [Cu(gly)dppz]ClO4 (1) (gly=glycinato) was synthesized by
modifying a general synthetic method previously reported [33,37]. In
detail, a mixture of glycine (75.1 mg, 1.0 mmol) and NaOH (40 mg,
1.0 mmol) in 10 ml of deionized water was added to an aqueous solu-
tion (25 ml) of Cu(ClO4)2·6H2O (370.0 mg, 1.0 mmol) under constant
stirring for 30 min. Subsequently, an ethanol solution (10 ml) of the
heterocyclic base dppz (282.0 mg, 1.0 mmol) was added dropwise.
The resulting white–blue mixture was stirred for 4 h at room tempera-
ture. The precipitate was ﬁltered, washed with diethyl ether and cold
aqueous methanol before drying under vacuum. The solid was
recrystallized in a 50% v/v H2O/MeOH solution, yielding blue crystals
suitable for X-ray diffraction analysis. Yield=85%.
The product was characterized by elemental analysis, FT-IR and
UV–vis spectroscopy. CuC20H14N5O6Cl a) anal. calcd.: C, 46.25; H,
2.72; N, 13.48; found: C, 46.30; H, 2.47; N, 13.10. b) FT-IR (cm−1):
(Nujol): 3353w, 2900mb, 1631s, 1582s, 1645vs, 1376vs, 1095s,
1075s, 826w, 765m, 732s, 625m, 582w, 431w. c) Electronic absorp-
tion in aqueous Tris–HCl 1 mM buffer [nm (ε, M−1 cm−1)]: 275
(5.77×104), 359 (1.15×104), 377 (1.19×104).
2.3. X-ray data collection and structure reﬁnement
Sea-green single crystals suitable for X-ray structural analysis were
selected from the crystals obtained from an H2O/MeOH solution. Data
were collected at room temperature with a Bruker APEX II CCD
area-detector diffractometer and graphite-monochromatizedMo-Kα ra-
diation (λ=0.71073 Å). Data collection, cell reﬁnement, data reduction
and absorption correction by multi-scan method were performed by
Bruker software [55]. The structure was solved by direct methods
using SHELXS97 [55]. The non-hydrogen atoms were reﬁned anisotrop-
ically by the full-matrix least-squares method on F2 using SHELXL97
[56]. All the H atoms were introduced in calculated positions and
constrained to ride on their parent atoms. The crystal and experimental
data are listed in Table 1. Selected bond distances and angles are given in
Table 2. Atomic coordinates, the full list of bond lengths and angles, an-
isotropic displacement parameters, hydrogen coordinates andhydrogen
bonds are reported as supplementary material in Tables S1–S5, while
the pictures are shown in Figs. 1 and S1–S3.
CCDC ID: 883024 contains the supplementary crystallographic
data for this paper. These data can be obtained free of charge from
the Cambridge Crystallographic Data Centre (CCDC) via www.ccdc.
cam.ac.uk/data_request/cif.
Table 1
Crystal data and structure reﬁnement for 1.
Empirical formula C20 H15 Cl Cu N5 O6
Formula weight 519.35
Temperature 296(2) K
Wavelength 0.71073 Å
Crystal system, space group Monoclinic, P21/c
Unit cell dimensions a=17.3944(5) Å α=90°.
b=8.2657(2) Å β=97.228°(2).
c=13.8451(4) Å γ=90°.
Volume 1974.79(9) Å3
Z, Calculated density 4, 1.629 Mg/m3
Absorption coefﬁcient 1.287 mm-1
F(000) 984
Crystal size 0.23 x 0.16 x 0.14 mm
Theta range for data collection 2.73 to 28.09 deg.
Limiting indices -22b=hb=23, -10b=kb=10, -18b=lb=18
Reﬂections collected / unique 65632 / 4798 [R(int)=0.0658]
Completeness to theta=28.09 99.7 %
Reﬁnement method Full-matrix least-squares on F2
Data / restraints / parameters 4798 / 0 / 335
Goodness-of-ﬁt on F2 1.075
Final R indices [I>2sigma(I)] R1=0.0336, wR2=0.0814
R indices (all data) R1=0.0474, wR2=0.0911
Largest diff. peak and hole 0.559 and −0.3695 e. Å-3
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2.4. Biological essays
2.4.1. Cell lines and culture conditions
The two human ATC cell lines 8505c and SW1736 were maintained
and grown in RPMI 1640 medium (RPMI = Roswell Park Memorial
Institute) and DMEM-high glucose (DMEM = Dulbecco`s Modiﬁed
Eagle Medium), respectively, containing 10% heat-inactivated fetal
bovine serum, 1% L-glutamine, 1% streptomycin and penicillin, under
standard culture conditions, at 37 °C and 5% CO2. All cell culture products
were purchased by PAA Laboratories, UK.
2.4.2. Drugs
Stock solutions of 1 and of cisplatin were diluted with sterile
serum-free culture medium to the desired concentration immediately
before each experiment.
2.4.3. Cytotoxicity assay
8505c and SW1736 cell lines were plated in 96-well plates with
100 μlmedium/well, at the seedingdensity of 3×103cells/well and incu-
bated overnight. After 24 h cellswere treatedwith1 andwith cisplatin at
the following concentrations: 0, 1, 5, 10 and 20 μM and cultured up to
72 h. Due to its known cytotoxicity, 20 μM cisplatin was not used. The
cell viability was evaluated performing a colorimetric assay using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
on both cell lines. At the time point 10 μM/well of MTT solution was
added and, after 4 h, removed and replaced by 100 μl of DMSO, to stop
the reaction. The plates were incubated for 5 min at room temperature
and the values of optical density detected by UV absorption spectrum
A
B
89.04o
Fig. 1. Perspective drawing of 1 with the atomic numbering scheme. Thermal ellipsoids are drawn at the 50% probability level. A: Fragment of 1D polymeric chain; B: coordination
around the Cu atom.
Table 2
Selected bond distances Å and angles (°)for 1.
Cu(1) \O(2) 1.932 (2)
Cu(1)\N(1) 2.008 (2)
Cu(1)\N(5) 2.011 (2)
Cu(1)\N(2) 2.015 (2)
Cu(1)\O(1)#1 2.251 (2)
Cu(1)\O(3) 2.741 (2)
N(3)\C(5) 1.322 (3)
N(3)\C(9) 1.351 (4)
O(1)\C(20) 1.239 (3)
O(1)\Cu(1)#2 2.251 (2)
O(2)\C(20) 1.275 (3)
C(21)\C(20) 1.504 (4)
Cu(1)\Cu(1)′ 5.8940 (2)
O(2)\Cu(1)\N(1) 167.55 (7)
O(2)\Cu(1)\N(5) 84.73 (8)
N(1)\Cu(1)\N(5) 99.30 (8)
O(2)\Cu(1)\N(2) 91.97 (7)
N(1)\Cu(1)\N(2) 81.37 (8)
N(5)\Cu(1)\N(2) 166.45 (8)
O(2)\Cu(1)\O(1)#1 98.02 (7)
N(1)\Cu(1)\O(1)#1 93.82 (7)
N(5)\Cu(1)\O(1)#1 89.19 (8)
N(2)\Cu(1)\O(1)#1 104.30 (7)
C(5)\N(3)\C(9) 116.8 (2)
C(20)\O(1)\Cu(1)#2 132.70 (17)
C(20)\O(2)\Cu(1) 116.22 (16)
N(5)\C(21)\C(20) 111.6 (2)
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at 550 nmwith a Microplate Reader, Model 550 (Bio-Rad). The concen-
trations that kill or inhibit cell growth by 50% (IC50) were estimated
from the resulting concentration–response curves, using the Gosa-ﬁt
software. Each experiment was repeated at least three times. The
percentage of cell viability was calculated as follows: [A(drug)−
A(blank)]/[A(control)−A(blank)]×100, where A is the absorbance.
Subsequently, SW1736 and 8505c cells were seeded at 3×103cells/
well and incubated overnight. The next day SW1736 and 8505c cell
lines were treated with 1 at the concentration of 2.5 μM and 1 μM and
with cisplatin at 2.5 μM and 6 μM, respectively up to 72 h. The viability
percentage was detected by performing theMTT assay, at the following
three time points: 24, 48 and 72 h. Each experiment was repeated at
least three times.
2.4.4. DNA-ladder (apoptosis assay)
For the DNA-laddering experiment, SW1736 and 8505c cells were
cultured in a medium containing 1 at the concentration of 2.5 μM and
1 μM, respectively, or cisplatin at 2.5 μM and 6 μM, respectively, for
48 h at a cell density of 1×106 cells in a T75 ﬂask, then scraped and
lysed at 37 °C for 2 h in a buffer containing 10 mM Tris–HCl (pH=8.0),
0.1 M EDTA (pH 8.0), 0.5% SDS, and 20 μg/ml RNase, DNase-free. Cell
lysates were treated with proteinase K at 100 μg/ml at 57 °C, overnight.
Cellular genomic DNA was precipitated with NaCl 5 M and isopropanol
for 30 min at −20 °C. The precipitate was washed in 70% ethanol and
resuspended in 10 μl Tris/EDTA. DNA concentration was evaluated by
The Qubit® ﬂuorometer (Invitrogen), then DNA (10 μg) was resolved
by electrophoresis in 1.5% agarose gel and stained in 5 μg/ml gelRed.
3. Results and discussion
3.1. Structural characterization
The synthesis of complex 1 straightforwardly proceeds at room tem-
perature, by mixing water solutions of Cu(ClO4)2·6H2O and of sodium
glycinate, with an ethanol solution of dppz, being the three reactants
in equimolar ratio, as sketched in the Scheme 1. The crystal structure
of 1 consists of a zig-zag 1D polymeric chain elongating parallel to the
crystallographic b axis (see Fig. 1A). The copper is bonded to the
bidentate N,N-donor dppz andmonoanionic N,O-donor glycinato ligand
through the amine nitrogen and carboxylate oxygen atoms; the second
carboxylic oxygen atom is axially bonded to an equivalent symmetric
copper atom. The X-ray structural features show how the perchlorate
anion employs one of its disordered oxygen atoms to complete the sec-
ond elongated axial site of the metal atom. 1 crystallizes in the mono-
clinic crystal system with the P21/c space group having in the
crystallographic asymmetric unit a copper(II) atom bonded to the
bidentate neutral N,N-donor dppz, a monoanionic N,O-donor ligand
and a perchlorate anion as shown in Fig. 1B. Selected bond distances
and angles are given in Table 2. Cu\N(1) and Cu\N(2) bond distances
of N,N dppz are: 2.008(2) Å and 2.015(2) Å respectively while the other
bond lengths in the equatorial plane are: Cu\N(5), 2.011(2)Å and
Cu\O(2), 1.932(2)Å. Equatorial bond distances as well as the bite
angle N(1) \Cu\N(2) and N(5)\Cu\O(2) (81.37(8)° and 84.70(8)°
respectively) are in good agreement with the corresponding ones
reported for related compounds [34,36,57,58]. The elongated axial posi-
tions are occupied by two oxygen atoms from the carboxylic group and
the perchlorate anion [Cu\O(1) 2.251(2)Å, Cu-O(3) 2.741(2)Å]. Contig-
uous dppz units in the polymeric chain assume an alternate comblike
disposition and a bidimensional polymeric surface is obtained by π–π
stacking interactions among the coordinated dppz ligands giving an
inter-planar distance of 3.671 Å of each monodimensional polymer
chain (Fig. S1). The whole molecular packing is also determined by sev-
eral hydrogen bonds and the usual van der Waals interactions.
3.2. Biological activity
ATC is an aggressive and usually fatal tumor withmedian survival of
4–12 month after diagnosis [5]. Rapid proliferation and heterogeneity
of ATC lesions, probably due to the nature of stem cells, make therapy
difﬁcult [59,60]. The current standard treatment includes surgery,
chemotherapy and radiotherapy, although it has been shown not to be
curative [61]. The anticancer compounds rose is quantitatively and quali-
tatively different and the therapeutic applications are limited by toxicity
and by drug resistance [62,63]. Neither doxorubicin, nor other drugs
such as cisplatin, bleomycin, ﬂuorouracil or cyclophospamide, showed
any real efﬁcacy in controlling the disease [64–66].
We have tested the potential anti-proliferative in vitro activity of the
copper complex 1 on two ATC cell lines: 8505c (Braf V600E/V600E) and
SW1736 (BrafWT/V600E) andwehave compared the results to cisplatin
treatment, the most common DNA crosslinker interfering with cell divi-
sion by mitosis, used both in in vitro and in vivo chemo-toxicity experi-
ments [67,68]. Both cell lines showed a dose-dependent cytotoxic
proﬁle when exposed at the treatment of 1, as well as of cisplatin (see
Fig. 2).
After 48 h of drug exposure the IC50 resulted cell lines related. In
particular, 1 showed a good antiproliferative activity in SW1736 cell
lines, with an IC50 value of 2.86±0.54 μM, to be compared with that
of cisplatin, IC50=2.50±0.40 μM. Remarkably, 1 exhibited an excellent
cytotoxic activity against 8505c, with an IC50 value of 1.05±0.48 μM,
considerably lower than the IC50 value shown by cisplatin against the
same cell line, 6.04±0.78 μM. In fact, the exposure to 1 for 72 h showed
a stronger lethal effect with respect to cisplatin treatment (Fig. 3A–B),
detectable already at 24 h of treatment. In details, when SW1736
were treated with 1 at 2.5 μM after 24 h, the viability decrease was
about 20% lower than that due to cisplatin treatment (see Fig. 3A); at
48 and at 72 h the viability was 49% and 33%, respectively (Fig. 3A).
On the other hand, when 8505cwas treatedwith 1 at 1 μM, the viability
rate was reduced to 53%, 50% and 24%, at 24, 48 and 72 h, respectively
(Fig. 3B). In both ATC cell lines a time-dependent effect of the IC50
was detected, with an optimum at 72 h (see Fig. 3A–B). Optical micros-
copy observations at 48 h revealed drastic cell phenotype changes: both
cell line cultures lost cellular adhesion and acquired a rounded shape
(see Fig. 3C), providing evidence of a typical apoptotic suffering pheno-
type. In this context, to discriminate between necrosis or apoptosis
Scheme 1. Synthesis of the copper(II) complex 1.
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dependent cell death, we have performed the DNA ladder assay. As
shown in Fig. 3D, DNA fragmentation, i.e. degradation into multiples
of 180-base pair long fragments, that is a typical hallmark of apoptosis
[69], was detected in both SW1736 and 8505c IC50 treated with 1, as
well as in cisplatin incubated cells.
On the whole, these data conﬁrm the excellent in vitro anti-
proliferative activity of the title copper complex, that is superior
than that shown by cisplatin in the case of 8505c ATC cell lines. It is
worth mentioning that metal complexes of gallium(III), tested on
the same 8505c cell lines, have recently shown IC50 values of more
than 10 times higher [63,70].
3.3. DNA-binding experiments
All the spectroscopic and especially viscosity measurements
performed on buffered aqueous solutions of 1 and DNA, conﬁrm
that the title cationic copper complex is a strong DNA-intercalator.
In detail, the UV–vis absorption spectrum of 1 in aqueous solution,
black line in Fig. 4, shows an intense band at 275 nm and aweaker mul-
tiplet in the range 340–400 nm, which is the typical infra-ligand (IL)
band of coordinated dppz [28]. Such IL bandwas used tomonitor the in-
teraction with DNA, because the latter shows no absorption in such
wavelength range. In fact, the absorption spectrum is considerablymod-
iﬁed by the addition of increasing amounts of DNA. In particular, the
maximum at IL band undergoes a bathochromic shift of about 6 nm up
to plateau at [DNAphosphate]/[1] molar ratios of about 5.
Moreover, the band at 377 nm shows also a hypochromic effect, i.e. a
decrease of the intensity, of about 50%, with an isosbestic point at
385 nm. The latter is indicative of the presence of only two copper(II)
complex species in solution, i.e. free and bound to DNA. The UV–vis titra-
tion data shown in Fig. 4 were analyzed by themethod proposed by Car-
ter et al. [71] to determine the intrinsic binding constant (Kb) and the
stoichiometry (s) of the 1-DNA system. In particular, s represents the
binding size in base pairs, i.e. the number of DNA base pairs involved in
the bond with the metal complex. In detail, the absorbance values at
375 nm were plotted in the inset of Fig. 4 as (εa−εf)/(εb−εf) vs the
molar concentration of DNA in monomeric units (DNAphosphate) and ana-
lyzed by Eqs. (1a) and (1b) [28]. In Eqs. (1a) and (1b), Ct is the total
concentration of the metal complex, εf, equal to 1.19×104 M−1 cm−1,
was determined by a calibration curve of the isolated metal complex in
aqueous solution, following the Beer–Lambert law. εb, equal to
6.12×103 M−1 cm−1, was determined from the plateau of the plot,
where further addition of DNA did not cause any changes in the absorp-
tion spectrum. Finally, εa was determined as the ratio between the mea-
sured absorbance and the analytical molar concentration of 1. The Kb
and s values obtained were (2.1±0.1)×106 M−1 and 0.42±0.01, re-
spectively.
εa−εf
εb−εf
¼
b− b2 2K
2
bCt DNAphosphate½ 
s
 1=2
2KbCt
ð1aÞ
b ¼ 1þ KbCt þ
Kb DNAphosphate
h i
2s
ð1bÞ
Noteworthy, these values of Kb and of s are very similar to those
obtained by the same absorption titration method for the interaction
of [Ru(phen)2dppz]2+ with DNA [27]. This result indicates a similarity
between the title copper complex 1 and [Ru(phen)2dppz]2+ both in
the strength and in the stoichiometry, hence in the interaction mecha-
nism, of the metal complex–DNA binding.
The CD spectrum of DNA is consistentlymodiﬁed by the addition of 1
(see Fig. 5). In detail, by increasing the amount ofmetal complex in solu-
tion, both negative and positive bands are monotonously shifted toward
more positive values of the intensity and toward smaller wavelengths.
Moreover, a slight induced negative CD band appears in the range
280–330 nm. Glycine was chosen also because it is not chiral and as a
consequence it does not affect the circular dichroism of DNA. So, being
1 achiral, these results show that the DNA conformation is perturbed
only by the interactionwith the copper complex. The observedmodiﬁca-
tions of the DNA CD spectrum reveal the occurrence of structural
Fig. 2. Proliferation assay (MTT) in SW1736 (up) and 8505c (down) cells after 48 h of treatment with cisplatin (0, 1, 5, 10 μM) and 1 (0, 1, 5, 10, 20 μM).
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changes of the DNA double helix following its interaction with 1 and are
in agreement with the hypothesis of DNA-intercalation.
The viscosity measurements are the most indicative results of the
occurrence of DNA-intercalation. It is in fact known that molecules that
are able to intercalate DNA typically induce unwinding of the double
helix and elongation of the DNA rods, giving rise to an increase of solution
viscosity [72]. As shown in Fig. 6, the relative viscosity of DNA solutions, in
the presence of 1 increases already at very small values of [1]/DNA-
phosphate] molar ratios. Interestingly, the observed trend of the relative vis-
cosity of DNA vs. the [1]/[DNAphosphate] molar ratio is analogous to that
obtained in the presence of known DNA intercalators, such as ethidium
bromide [73].
It iswell known that the acceptedmechanismof the cytotoxic activity
of cisplatin and doxorubicin, as anticancer drugs, relies on the capacity of
Fig. 3. Evaluation of the cytotoxicity, by MTT essays, of cisplatin and of 1 on SW1736 and 8505c cells, at 24 h, 48 h and 72 h. A) Cytotoxic effect of 2.5 μM cisplatin and of 2.8 μM 1 in
SW1736 cells. B) Cytotoxic effect of 6.0 μM cisplatin and of 1.0 μM 1 in 8505c cells. C) Cell phenotypes modiﬁcation 1-treatment dependent. SW1736 cells and SW1736 cells plus 1
(upper), 8505c cells and 8505c cells plus 1 (lower). Both cell lines show a rounded shape after exposure to 1 for 48 h. D) DNA fragmentation in SW1736 and 8505c cells after 72 h.
Lane-1: SW1736 CN; lane-2: SW1736 plus cisplatin; lane-3: SW1736 plus 1; lane-4: 8505c CN; lane-5: 8505c plus cisplatin; lane-6: 8505c plus 1; CN: cells without treatment;
L: DNA laddering marker (100 bp).
Fig. 4. UV–vis titration of 1 with increasing amount of DNA in Tris–HCl 1.0 mM,
pH=7.5. [1]=40 μM (black solid line); [DNAphosphate]=2, 4, 8, 12, 16, 20, 28, 40, 80,
200 μM; inset: plot of (εb−εf)/(εa−εf), at 375 nm, vs. [DNAphosphate] (see text).
Fig. 5. Circular dichroism spectra of DNA solutions in Tris–HCl 1.0 mM, pH=7.5, in the
presence of increasing amounts of 1. [DNAphosphate]=50 μM (black solid line); [1]=0,
5, 12.5, 25, 35.7 μM.
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cisplatin to covalently bind theN7 atom of two guanine nucleobases [6,7]
and of doxorubicin to intercalate into stacked DNA base pairs [8]. The
DNA-binding experiments unequivocally show that 1 tightly binds
DNA, presumably through the intercalation of the dppzmoiety, although
the occurrence of a covalent binding involving the metal atom cannot be
excluded. In fact, the apical coordination sites of the copper atom in the
[Cu(dppz)(gly)]+ unit can be replaced by coordinating N and O donor
atoms of the DNA bases. As a consequence, it is possible to hypothesize
that the mechanism of the cytotoxic activity of the title copper(II) com-
plex could be induced by bothDNA-intercalation andmetal coordination,
as recently pointed out by Liu and Sadler [11].
4. Conclusions
The heteroleptic dppz and glycinato complex of copper(II) 1 has
been synthesized and characterized. Cytotoxicity assays provided evi-
dence for a remarkable anti-proliferative activity of 1 against two
human anaplastic thyroid cancer cell lines, SW1736 and 8505c, with
an IC50 value of 2.53±0.54 μM and 1.05±0.48 μM, respectively. The
latter, in particular, is lower than the analogous IC50 value shown by cis-
platin toward the same cell line, 6.03±0.78 μM. Furthermore, cell
death occurs by apoptosis in both cell lines, as conﬁrmed by optical mi-
croscopy observations andDNA ladder assays, at 48 h of treatmentwith
1. The strongest lethal effect of 1 in 8505c cell lines compared to that in
SW1736 cell lines suggests the existence of a cytotype correlation.
DNA-binding studies, performed by absorption spectrophotometry,
circular dichroism and viscosimetry measurements have shown that
themetal complex is a strongDNA-intercalator, with a binding constant
between 1 and DNA of 2.1×106 M−1. Although the biological essays
furnish no direct evidence that the copper(II) complex was transferred
to the cell nucleus, such data suggest that DNA-binding might be re-
sponsible for the observed antiproliferative activity shown by title com-
pound 1.
The results obtained in the present work conﬁrm that transition
metal complexes of the dppz ligands are efﬁcient DNA-binders and
that glycinato is a promising ancillary ligand in dppz metal complexes
with anticancer activity.
Abbreviations
ATC Anaplastic thyroid carcinoma
phen 1,10-phenanthroline
CD circular dichroism
dppz dipyrido[3,2-a:2',3'-c]phenazine
gly glycinato
IC50 half maximal inhibitory concentration
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